Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
Authors
Keywords
-
Journal
CELL PROLIFERATION
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-03-03
DOI
10.1111/cpr.13009
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer
- (2020) Kiera Roubal et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- FGFR3 signaling and function in triple negative breast cancer
- (2020) Nicole J. Chew et al. Cell Communication and Signaling
- Second-line lenvatinib in patients with recurrent endometrial cancer
- (2020) Ignace Vergote et al. GYNECOLOGIC ONCOLOGY
- High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers
- (2020) Joon Young Hur et al. PATHOLOGY RESEARCH AND PRACTICE
- Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy
- (2020) Kenji Ichikawa et al. Scientific Reports
- Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma
- (2020) Haijing Deng et al. Liver Cancer
- Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
- (2020) Yolla Haibe et al. Frontiers in Oncology
- Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma
- (2020) Eun Kyung Kim et al. BMC CANCER
- Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
- (2020) Young K. Chae et al. JOURNAL OF CLINICAL ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
- (2020) Jianhui Ma et al. Frontiers in Oncology
- Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial
- (2020) Akihito Kawazoe et al. LANCET ONCOLOGY
- Fibroblast growth factor‐2, derived from cancer‐associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling
- (2020) Jinyoung Suh et al. MOLECULAR CARCINOGENESIS
- Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions
- (2020) Anna Luisa Di Stefano et al. NEURO-ONCOLOGY
- FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy
- (2020) Jae Hong Im et al. Nature Communications
- Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality
- (2020) Xiaohan Zhou et al. Frontiers in Oncology
- Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors
- (2019) Ravi Paluri et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer
- (2019) Shunji Takahashi et al. Future Oncology
- Novel TG-FGFR1 and TRIM33-NTRK1 transcript fusions in papillary thyroid carcinoma
- (2019) Aleksandra Pfeifer et al. GENES CHROMOSOMES & CANCER
- Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
- (2019) Luigi Formisano et al. Nature Communications
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- (2019) Vicky Makker et al. LANCET ONCOLOGY
- Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer
- (2019) Angeles Alvarez Secord et al. GYNECOLOGIC ONCOLOGY
- Diagnostic potential of TERT promoter and FGFR 3 mutations in urinary cell‐free DNA in upper tract urothelial carcinoma
- (2019) Yujiro Hayashi et al. CANCER SCIENCE
- The Intersection between Tumor Angiogenesis and Immune Suppression
- (2019) Osama E. Rahma et al. CLINICAL CANCER RESEARCH
- Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
- (2019) Rastilav Bahleda et al. CLINICAL CANCER RESEARCH
- Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase 3 study design
- (2019) Daniel VT Catenacci et al. Future Oncology
- A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies
- (2019) Noboru Yamamoto et al. INVESTIGATIONAL NEW DRUGS
- Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification Detected by Droplet Digital Polymerase Chain Reaction (ddPCR) Is a Prognostic Factor in Colorectal Cancers
- (2019) Jeong Mo Bae et al. Cancer Research and Treatment
- Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
- (2019) Giorgio V Scagliotti et al. Lancet Respiratory Medicine
- SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
- (2019) Charu Aggarwal et al. Journal of Thoracic Oncology
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma
- (2019) Amit Mahipal et al. CANCER TREATMENT REVIEWS
- Insight into ponatinib resistance mechanisms in rhabdomyosarcoma caused by the mutations in FGFR4 tyrosine kinase using molecular modeling strategies
- (2019) Chao Wu et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer
- (2019) Kathryn C. Arbour et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
- (2019) Rina Hui et al. CLINICAL CANCER RESEARCH
- Recent advance in the development of novel, selective and potent FGFR inhibitors
- (2019) Feng-Tao Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
- (2019) Takafumi Koyama et al. CANCER SCIENCE
- Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma
- (2019) Fangda Li et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor
- (2018) S Verstovsek et al. ANNALS OF ONCOLOGY
- Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
- (2018) E Van Cutsem et al. ANNALS OF ONCOLOGY
- Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
- (2018) Baohui Han et al. BRITISH JOURNAL OF CANCER
- Sequential delivery of VEGF, FGF-2 and PDGF from the polymeric system enhance HUVECs angiogenesis in vitro and CAM angiogenesis
- (2018) Yan Bai et al. CELLULAR IMMUNOLOGY
- Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients With Refractory Metastatic Soft Tissue Sarcoma
- (2018) Yihebali Chi et al. CLINICAL CANCER RESEARCH
- Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors
- (2018) Manman Wei et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1
- (2018) Binyan Lin et al. GENE
- Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population
- (2018) Xiao-Hong Pu et al. HUMAN PATHOLOGY
- FGFR2b activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer
- (2018) Samantha J. Stehbens et al. JOURNAL OF CELL SCIENCE
- Design, synthesis and biological evaluation of 4-bromo-N-(3,5-dimethoxyphenyl)benzamide derivatives as novel FGFR1 inhibitors for treatment of non-small cell lung cancer
- (2018) Zixin Xie et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium
- (2018) Sarah A. Best et al. ONCOGENE
- Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer
- (2018) Cathy B. Moelans et al. Oncotarget
- The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction
- (2018) Álvaro Quintanal-Villalonga et al. Scientific Reports
- Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions
- (2018) Ryo Tamura et al. Oncogenesis
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity
- (2018) Ju Yang et al. Frontiers in Immunology
- Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy
- (2018) Zhao Yang et al. EBioMedicine
- An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy
- (2018) Noboru Yamamoto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors
- (2018) Tuan Zea Tan et al. EUROPEAN UROLOGY
- Lenvatinib as a therapy for unresectable hepatocellular carcinoma
- (2018) Andrea Spallanzani et al. Expert Review of Anticancer Therapy
- Diagnostic and Prognostic Implications of FGFR3high/Ki67high Papillary Bladder Cancers
- (2018) Mirja Geelvink et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
- (2018) Guoshuang Shen et al. Journal of Hematology & Oncology
- Trametinib for progressive pediatric low-grade gliomas
- (2018) Maria Kondyli et al. JOURNAL OF NEURO-ONCOLOGY
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-Tissue Sarcoma: Potential Therapeutic implication for Synovial Sarcoma
- (2018) Parag P Patwardhan et al. MOLECULAR CANCER THERAPEUTICS
- Anlotinib for the Treatment of Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer
- (2018) Yongkun Sun et al. THYROID
- FGFR3 mRNA overexpression defines a subset of oligometastatic colorectal cancers with worse prognosis
- (2018) Julia Elisabeth Fromme et al. Oncotarget
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Baohui Han et al. JAMA Oncology
- Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting
- (2018) Brendan Farrell et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- (2018) Vincenzo Mazzaferro et al. BRITISH JOURNAL OF CANCER
- Sorafenib: key lessons from over 10 years of experience
- (2018) Bernard Escudier et al. Expert Review of Anticancer Therapy
- ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
- (2018) Tim H. Holmström et al. MOLECULAR CANCER THERAPEUTICS
- Fibroblast growth factor receptors as treatment targets in clinical oncology
- (2018) Masaru Katoh Nature Reviews Clinical Oncology
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
- (2018) Elias Jabbour et al. Lancet Haematology
- Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors
- (2017) Yang Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study
- (2017) John K. Chan et al. GYNECOLOGIC ONCOLOGY
- Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study
- (2017) Arinobu Tojo et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study
- (2017) Hideo Saka et al. INVESTIGATIONAL NEW DRUGS
- Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
- (2017) Tomohiro Nishina et al. INVESTIGATIONAL NEW DRUGS
- Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases
- (2017) Frank Hilberg et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
- (2017) Margherita Nannini et al. Journal of Translational Medicine
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group
- (2017) Scott A. Laurie et al. LUNG CANCER
- Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
- (2017) Timothy P.S. Perera et al. MOLECULAR CANCER THERAPEUTICS
- FGF-dependent metabolic control of vascular development
- (2017) Pengchun Yu et al. NATURE
- A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
- (2017) Michael Michael et al. Targeted Oncology
- Activating FGFR1 Mutations in Sporadic Pheochromocytomas
- (2017) Jenny Welander et al. WORLD JOURNAL OF SURGERY
- Copy number profiles of paired primary and metastatic colorectal cancers
- (2017) Futoshi Kawamata et al. Oncotarget
- FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition
- (2017) Sang Hee Cho et al. Cancer Research and Treatment
- Identification of a FGFR3-TACC3 fusion in esophageal cancer
- (2016) T. Mizukami et al. ANNALS OF ONCOLOGY
- Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment
- (2016) Takuji Okusaka et al. CANCER SCIENCE
- Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma
- (2016) Priya Chudasama et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
- (2016) Noah M. Hahn et al. CLINICAL CANCER RESEARCH
- Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
- (2016) Ann-Lii Cheng et al. HEPATOLOGY
- FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
- (2016) MASARU KATOH INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Phase I trial of dovitinib (TKI258) in recurrent glioblastoma
- (2016) Niklas Schäfer et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
- (2016) Kenji Ikeda et al. JOURNAL OF GASTROENTEROLOGY
- Regulation of fibroblast growth factor 15/19 and 21 on metabolism: in the fed or fasted state
- (2016) Dandan Guan et al. Journal of Translational Medicine
- Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) Andreas du Bois et al. LANCET ONCOLOGY
- Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
- (2016) Jeffrey H Lipton et al. LANCET ONCOLOGY
- A phase II study of nintedanib in patients with relapsed small cell lung cancer
- (2016) Ji-Youn Han et al. LUNG CANCER
- Characterization of FN1–FGFR1 and novel FN1–FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors
- (2016) Jen-Chieh Lee et al. MODERN PATHOLOGY
- E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
- (2016) S. Watanabe Miyano et al. MOLECULAR CANCER THERAPEUTICS
- ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma
- (2016) Takashi Futami et al. MOLECULAR CANCER THERAPEUTICS
- Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
- (2016) Gianantonio Rosti et al. Nature Reviews Clinical Oncology
- Ten years of anti-vascular endothelial growth factor therapy
- (2016) Napoleone Ferrara et al. NATURE REVIEWS DRUG DISCOVERY
- Mechanisms and regulation of endothelial VEGF receptor signalling
- (2016) Michael Simons et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Fibroblast growth factors, old kids on the new block
- (2016) Xiaokun Li et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Nintedanib in NSCLC: evidence to date and place in therapy
- (2016) Giuseppe Bronte et al. Therapeutic Advances in Medical Oncology
- Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
- (2016) Terence G. Hall et al. PLoS One
- A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
- (2016) Christoph Schliemann et al. PLoS One
- Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours
- (2015) Rastislav Bahleda et al. BRITISH JOURNAL OF CANCER
- Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma
- (2015) Bhumsuk Keam et al. CANCER
- Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer
- (2015) Niranjan Awasthi et al. CANCER LETTERS
- Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2
- (2015) J. Tanizaki et al. CANCER RESEARCH
- Targeting FGFR Signaling in Cancer
- (2015) M. Touat et al. CLINICAL CANCER RESEARCH
- Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma
- (2015) K. Agelopoulos et al. CLINICAL CANCER RESEARCH
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
- (2015) M. Schlumberger et al. CLINICAL CANCER RESEARCH
- An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer
- (2015) Sun Min Lim et al. EUROPEAN JOURNAL OF CANCER
- The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis
- (2015) Roberto Ronca et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity
- (2015) Camillo Porta et al. Future Oncology
- Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer
- (2015) Anna Fischbach et al. HISTOPATHOLOGY
- Fibroblast growth factor receptor 1 gene amplification in gastric adenocarcinoma
- (2015) Manuel H. Schäfer et al. HUMAN PATHOLOGY
- Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
- (2015) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study
- (2015) Gottfried E Konecny et al. LANCET ONCOLOGY
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site
- (2015) Vijay K. Ulaganathan et al. NATURE
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review
- (2015) Norbertus A. Ipenburg et al. Targeted Oncology
- The Fibroblast Growth Factor signaling pathway
- (2015) David M. Ornitz et al. Wiley Interdisciplinary Reviews-Developmental Biology
- Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma
- (2015) Koos Koole et al. Cancer Medicine
- Nintedanib in non-small cell lung cancer: from preclinical to approval
- (2015) Christian Caglevic et al. Therapeutic Advances in Respiratory Disease
- Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study
- (2015) Preetesh Jain et al. Lancet Haematology
- Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy
- (2015) Nobuyuki Itoh et al. Frontiers in Endocrinology
- Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma
- (2015) Hyo Song Kim et al. Oncotarget
- Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
- (2014) J.- C. Soria et al. ANNALS OF ONCOLOGY
- Low Prognostic Implication of Fibroblast Growth Factor Family Activation in Triple-negative Breast Cancer Subsets
- (2014) Hee Jin Lee et al. ANNALS OF SURGICAL ONCOLOGY
- Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib
- (2014) Noriyuki Koyama et al. BMC CANCER
- Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer
- (2014) N Cihoric et al. BRITISH JOURNAL OF CANCER
- Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
- (2014) B. Escudier et al. CLINICAL CANCER RESEARCH
- A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer
- (2014) Thomas Powles et al. EUROPEAN JOURNAL OF CANCER
- Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
- (2014) Matthew I. Milowsky et al. EUROPEAN JOURNAL OF CANCER
- A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
- (2014) Don S. Dizon et al. GYNECOLOGIC ONCOLOGY
- Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
- (2014) Masatoshi Kudo et al. HEPATOLOGY
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic therapy in HCC: Lessons from brivanib
- (2014) David Bolos et al. JOURNAL OF HEPATOLOGY
- Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors
- (2014) R. S. K. Vijayan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas
- (2014) Andrew D. Norden et al. JOURNAL OF NEURO-ONCOLOGY
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
- (2014) Martin Reck et al. LANCET ONCOLOGY
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
- (2014) Robert J Motzer et al. LANCET ONCOLOGY
- Improved Survival with Bevacizumab in Advanced Cervical Cancer
- (2014) Krishnansu S. Tewari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis
- (2014) Sunday S. Oladipupo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy
- (2014) M. Fernanda Amary et al. Cancer Medicine
- Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer
- (2013) M Nishio et al. BRITISH JOURNAL OF CANCER
- Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
- (2013) E. Angevin et al. CLINICAL CANCER RESEARCH
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
- (2013) F. Andre et al. CLINICAL CANCER RESEARCH
- Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-TypeK-RASColorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial
- (2013) Lillian L. Siu et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations
- (2013) Patricia A. Tang et al. Therapeutic Advances in Gastroenterology
- FGFR2 gene amplification and clinicopathological features in gastric cancer
- (2012) K Matsumoto et al. BRITISH JOURNAL OF CANCER
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
- (2012) D S Boss et al. BRITISH JOURNAL OF CANCER
- AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
- (2012) P. R. Gavine et al. CANCER RESEARCH
- Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2012) R. S. Finn et al. CLINICAL CANCER RESEARCH
- Structural Basis for Selective Vascular Endothelial Growth Factor-A (VEGF-A) Binding to Neuropilin-1
- (2012) Matthew W. Parker et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme
- (2012) Aida Muhic et al. JOURNAL OF NEURO-ONCOLOGY
- Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis
- (2012) R. Cao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of fibroblast growth factor signaling in vascular formation and maintenance: orchestrating signaling networks as an integrated system
- (2012) Masahiro Murakami et al. Wiley Interdisciplinary Reviews-Systems Biology and Medicine
- E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
- (2011) Ezia Bello et al. CANCER RESEARCH
- Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2011) J.-W. Park et al. CLINICAL CANCER RESEARCH
- Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma
- (2011) K. B. Kim et al. CLINICAL CANCER RESEARCH
- Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
- (2011) Elizabeth Allen et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
- (2011) K. Yamada et al. CLINICAL CANCER RESEARCH
- Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer
- (2011) Y. Dodurga et al. GENETICS AND MOLECULAR RESEARCH
- FGF-dependent regulation of VEGF receptor 2 expression in mice
- (2011) Masahiro Murakami et al. JOURNAL OF CLINICAL INVESTIGATION
- A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
- (2011) G. Zhao et al. MOLECULAR CANCER THERAPEUTICS
- A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
- (2010) D. J. Jonker et al. ANNALS OF ONCOLOGY
- Signal Transducers and Activators of Transcription-3 Binding to the Fibroblast Growth Factor Receptor Is Activated by Receptor Amplification
- (2010) A. A. Dudka et al. CANCER RESEARCH
- Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease
- (2010) Nobuyuki Itoh CELL AND TISSUE RESEARCH
- Biology of FGFRL1, the fifth fibroblast growth factor receptor
- (2010) Beat Trueb CELLULAR AND MOLECULAR LIFE SCIENCES
- Binding to the Extracellular Matrix and Proteolytic Processing: Two Key Mechanisms Regulating Vascular Endothelial Growth Factor Action
- (2010) Napoleone Ferrara MOLECULAR BIOLOGY OF THE CELL
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
- (2010) N Turner et al. ONCOGENE
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- The Role of Fibroblast Growth Factors in Tumor Growth
- (2009) M. Korc et al. CURRENT CANCER DRUG TARGETS
- Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: An approach to identify candidate genes involved in tumor development
- (2009) Edoardo Missiaglia et al. GENES CHROMOSOMES & CANCER
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started